Stanford Study Links Estrogen-Only Hormone Therapy to Lower Alzheimer's Risk
A large-scale study conducted by researchers at Stanford University has found that women who utilize estrogen-only menopausal hormone therapy (MHT) may have a reduced likelihood of developing Alzheimer's disease and related dementia. Published in the journal Neurology on August 12, the study analyzed post-mortem data from 21,462 participants, specifically comparing 258 women who reported using estrogen-only MHT with approximately 2,701 women who did not use any form of hormone therapy.
The researchers focused on identifying Alzheimer's-related brain changes, including amyloid plaques and neurofibrillary tangles, which are key indicators of the disease. The results revealed that women who had taken estrogen-only therapy exhibited a 35% lower chance of Alzheimer's pathology and a 39% lower risk of dementia over their lifetimes. Additionally, among some living participants, those who had used estrogen-only therapy performed better on memory tests and demonstrated greater independence in daily activities. Supporting evidence was also found in biomarkers present in blood and cerebrospinal fluid.
The average age of participants was around 70 years, and the study suggests that the timing of hormone therapy may play a crucial role in its effectiveness. Recent findings indicate that starting menopausal hormone therapy during or shortly after menopause could yield greater benefits.
These findings present a notable shift from previous research, which had suggested that hormone therapy might increase dementia risk. Co-author Jennifer Bruno, PhD, highlighted the neuroprotective properties of estrogen, stating that it can influence the pathways associated with amyloid and tau, both of which are critical in Alzheimer's pathology. Furthermore, she noted that estrogen supports synaptic plasticity, reduces neuroinflammation, and maintains the integrity of the blood-brain barrier.
Despite these promising results, the study does have limitations. As an observational study, it can only establish associations rather than causation. Senior author Hadi Hosseini, PhD, pointed out that there may be unmeasured differences between women who used hormone therapy and those who did not, such as overall health status or healthcare engagement.
While the findings do not alter current clinical recommendations regarding hormone therapy, they underscore the necessity for well-structured clinical trials to validate these observations and explore the potential cognitive benefits of menopausal hormone therapy. Bruno emphasized that these results are significant and call for further investigation rather than immediate changes in treatment protocols.
The study was funded by the National Institutes of Health, and the researchers advocate for prospective, biomarker-based trials that follow women through different stages of menopause to better understand the effects of hormone therapy on brain health.




